Non-Invasive Monitoring Systems Announces 2nd Quarter Results.Business Editors/Technology & Medical Writers MIAMI BEACH Miami Beach, city (1990 pop. 92,639), Dade co., SE Fla., on an island between Biscayne Bay and the Atlantic Ocean; inc. 1915. It is connected to Miami by four causeways. , Fla.--(BUSINESS WIRE)--March 15, 2000 Non-Invasive Monitoring Systems, Inc. (Nims) (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :NIMU NIMU Non-Iterative Multi-User NIMU National Iron Molders Union ) announced unaudited results for second quarter and six months ended January 31, 2000. Non-Invasive Monitoring Systems, Inc. (the "Company" or "Nims") is engaged in research and development of computer assisted, non-invasive monitoring devices and related software designed to detect abnormal respiratory, cardiac, and other medical conditions See carpal tunnel syndrome, computer vision syndrome, dry eyes and deep vein thrombosis. from sensors placed externally on the body's surface. These devices provide diagnostic information regarding cardiorespiratory car·di·o·res·pi·ra·to·ry adj. Of or relating to the heart and the respiratory system. Adj. 1. cardiorespiratory - of or pertaining to or affecting both the heart and the lungs and their functions; "cardiopulmonary and sleep disorders Sleep Disorders Definition Sleep disorders are a group of syndromes characterized by disturbance in the patient's amount of sleep, quality or timing of sleep, or in behaviors or physiological conditions associated with sleep. in infants, children and adults; in addition, alarms are sounded for adverse cardiac and respiratory events in critically ill patients. The Company also develops non-invasive, therapeutic, cardiorespiratory devices. Total revenue for second quarter ended January 31, 2000, was approximately $233,572 as compared to approximately $81,136 for second quarter of fiscal year 1999. For second quarter ended January 31, 2000, Nims reported a profit of approximately $75,233 as compared to a net loss of approximately $116,952 for second quarter of fiscal 1999. Total revenue for six months ended January 31, 2000 was approximately $316,613 compared to $153,473 for six months of fiscal 1999. For the six months ended January 31, 2000, Nims reported a loss of approximately $24,032 as compared to a net loss of approximately $249,053 for six months ended January 31, 1999. The profit this quarter compared to one year ago is attributed to increase of product sales and the research and development contract between LifeShirt.com, Inc. and Nims executed in November 1999. LifeShirt.com, Inc. (Ojai, CA) is a start-up eCare company that plans to market the LifeShirt system, a computerized shirt that monitors and records physical signs into a small digital recorder See DVR and CD-R. and uploads the encrypted data over the Internet for analysis and display on a secure website for Physician review. By adapting Nims' hospital-tested technology for transmission over the Internet, LifeShirt has potential for providing vital information to physicians as an aid to management and prevention of acute problems in such conditions as asthma, chronic heart failure, sleep disorders, anxiety, coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. and cancer pain. Receipt of payments from LifeShirt.com, Inc. for research and development of the LifeShirt system began in November 1999 and product launch is planned for late fall 2000. Nims holds an equity position in LifeShirt.com, Inc. as well as a royalty arrangement on sales of the system. Nims continues development of its therapeutic motion platform (patent pending) that produces repetitive head to foot motion. In experiments, this device produces Non-Invasive Motion Ventilation, a new means to achieve ventilation at breath volumes lower than natural breathing and with rates that are more rapid. This modality modality /mo·dal·i·ty/ (mo-dal´i-te) 1. a method of application of, or the employment of, any therapeutic agent, especially a physical agent. 2. does not impose positive pressure on the lungs and reduces the potential for damage to lung tissue as has been demonstrated with conventional mechanical ventilators. Except for historical information, this press release contains, forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. regarding the Company's operations, performance, financial condition, business strategies, margins and sales information and are made pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the private securities litigation reform act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. For this purpose, any statements contained in this Release that are not statements of historical fact may be deemed to be forward-looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control, and actual results could differ materially depending on a variety of important factors, including those described in this Release and the Company's filings with the Securities and Exchange Commission.
Consolidated Financial Summary
Three Months Ended Six Months Ended
January 31 January 31
1999 2000 1999 2000
Total Revenues $81,136 $233,572 $153,473 $316,613
Net (Loss) Income $(116,853) $75,233 $(249,053) $(24,032)
Weighted Average
Number of Shares
Outstanding 16,514,726 21,514,726 16,514,726 21,514,726
Income (Loss) per Share $(0.007) $0.003 $(0.015) $(0.001)
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion